Morgan Stanley kept its positive rating on BridgeBio Pharma and raised the price target from $87 to $88.

BBIO · BridgeBio Pharma

The AI's read

This gives investors a slightly more favorable outside view of BridgeBio, but it does not show that the company’s sales, profits, or drug progress changed. The rating stayed the same, so this is a limited positive signal, not proof of stronger business results.